Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.47 |
| ▸ | CDK2 | P24941 | 8/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798773 | 0.81 | AURKA (0.43) | AURKACDK2MAPK1NOTUM | |
| SCHEMBL2787595 | 0.81 | AURKA (0.69) | AURKACDK2MAPK1 | |
| SCHEMBL5403606 | 0.80 | AURKA (0.42) | AURKACDK2MAPK1NOTUM | |
| SCHEMBL5396690 | 0.80 | AURKA (0.42) | AURKACDK2MAPK1NOTUM | |
| SCHEMBL18131435 | 0.80 | NOTUM (0.47) | AURKACDK2MAPK1PDK1NOTUM | |
| SCHEMBL14252620 | 0.80 | AURKA (0.75) | AURKACDK2MAPK1 | |
| SCHEMBL12020865 | 0.80 | AURKA (0.75) | AURKACDK2MAPK1 | |
| SCHEMBL5407257 | 0.79 | AURKA (0.70) | AURKACDK2MAPK1 | |
| SCHEMBL5416820 | 0.79 | AURKA (0.54) | AURKACDK2MAPK1ATM | |
| SCHEMBL27582159 | 0.79 | RAB9A (0.43) | AURKACDK2MEN1KMT2ALDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345054-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-18 | — | — | US | disclosed |
| US-7304061-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050234059-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-10-20 | — | — | US | disclosed |
| EP-1506189-A1 | PYRROLE DERIVATIVES AS INHIBITORS OF ERK2 AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040029857-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-12 | — | — | US | disclosed |
| WO-2003091246-A1 | PYRROLE DERIVATIVES AS INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234059-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CDK2, MAPK3, CDK1 | AURKA 92/4885CDK2 1/4885MAPK1 8/4885 |
| US-20040029857-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CDK2, CDK1, CDK3 | AURKA 54/4885CDK2 1/4885MAPK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.